# RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR

> **NCT02255422** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 53 (actual)

## Conditions studied

- MItochondrial Myopathies

## Interventions

- **DRUG:** Omaveloxolone capsules, 2.5 mg
- **DRUG:** omaveloxolone capsules, 5 mg
- **DRUG:** omaveloxolone capsules, 10 mg
- **DRUG:** Placebo capsules
- **DRUG:** omaveloxolone capsules, 20 mg
- **DRUG:** omaveloxolone capsules, 40 mg
- **DRUG:** omaveloxolone capsules, 80 mg
- **DRUG:** omaveloxolone capsules, 160 mg

## Key facts

- **NCT ID:** NCT02255422
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-05
- **Primary completion:** 2017-11-02
- **Final completion:** 2017-11-30
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2025-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02255422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02255422, "RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02255422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*